Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Evaluate the Effectiveness and Safety of At-Home Rehabilitation Gait Training Using a Hip-assisted Wearable Robot in Stroke Patients

NCT07716475 · tracked via the Priya Life Science South Korea tracker
Phase
Not applicable
Started
2026-07-06
Last updated
2026-07-21

Condition(s) studied

Stroke

Investigational drug(s) / intervention(s)

hip-assisted wearable robot

hip-assisted wearable robot: A hip-assisted wearable robot (wearable gait-assist robot) that assists flexion and extension of the hip joint during walking. The battery-powered device is controlled through a paired mobile application via Bluetooth, and its assistive force can be adjusted to each participant. A visiting physical or occupational therapist applies the device and delivers gait training at the participant's home for 4 sessions over 2 weeks, 30 minutes per session, under a physician's prescription and supervision.

Study summary

The goal of this clinical trial is to learn whether a wearable monitoring system can help adults who have had a stroke get more out of a home exercise program. The system tracks how participants walk and move, then gives them feedback. Researchers want to know if this feedback improves walking, thinking and memory, and daily activity.

The wearable monitoring system has three parts:

A shoe insole sensor that measures how a person walks A wrist band that tracks daily activity, like a fitness watch A mobile app that gives feedback and lets participants report how they feel

The main questions this study aims to answer are:

Does feedback from the wearable system improve physical function, thinking and memory, and daily activity during a home exercise program? How satisfied are participants with using the wearable system?

Researchers will compare two groups. Both groups do the same home exercise program for 6 weeks. One group uses the wearable system and gets feedback. The other group does the program without the wearable system or feedback. This comparison shows whether the feedback itself makes a difference.

Who can take part: adults who have had a stroke and \[key eligibility in plain words, e.g., "can walk a short distance with or without help"\]. The study plans to enroll about \[number\] participants.

Participants in the wearable group will:

Get an insole sensor, a wrist activity tracker, and access to a mobile app Learn a home exercise program from the study team Wear the insole sensor and activity tracker while exercising at home for 6 weeks Use the app to see their feedback and report daily health information Complete a survey about their experience at the end

Participants in the comparison group will:

Do the same home exercise program for 6 weeks, without the wearable system or feedback.

Eligibility

Sex
ALL
Min age
19 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Adults aged 19 years or older and under 80 years 2. Persons diagnosed with cerebral infarction or intracerebral hemorrhage confirmed by magnetic resonance imaging or computed tomography 3. Persons for whom at least 1 month has elapsed since the diagnosis of stroke 4. Persons showing a spastic hemiplegic gait pattern due to stroke 5. Patients with a Functional Ambulatory Category score below 4 6. Persons who can sit without assistance at the edge of a bed and can stand for 10 seconds with or without assistance 7. Persons with sufficient cognitive ability to follow simple instructions and understand the content and purpose of the study (Mini-Mental State Examination score \>= 20) Exclusion Criteria: 1. Persons with contraindications to lower-extremity weight bearing, such as severe lower-extremity joint contracture or an untreated fracture 2. Persons for whom wearing the device is difficult due to skin disease or open wounds 3. Persons with a severe difference in the length of the two lower extremities 4. Persons with severe deformity or joint contracture in the lower extremities 5. Persons unable to maintain a sitting posture or a standing posture on their own 6. Persons with severe lower-extremity spasticity (Modified Ashworth Scale (MAS) grade 2 or higher) 7. Persons who cannot cooperate with gait therapy using the robot-assisted orthopedic exercise device due to severe cognitive decline (Mini-Mental State Examination score \< 20), delirium, or severe language function impairment 8. Persons who cannot maintain prolonged standing or walking due to underlying conditions such as orthostatic hypotension or reduced cardiopulmonary function 9. Persons with other concomitant conditions affecting gait, such as peripheral neuropathy or parkinsonism due to alcoholism or severe diabetes 10. Pregnant women or patients with the possibility of pregnancy 11. Persons currently participating in another clinical trial 12. Persons at high risk in the event of a fall or bleeding due to a coagulation disorder or the like 13. Persons with a height less than 140 cm or greater than 190 cm 14. Persons for whom wearing the robot is not possible 15. Persons with clinically significant findings that, in the medical judgment of the principal investigator or a sub-investigator, are considered inappropriate for this study other than the above

Primary outcome measure(s)

  • Telehealth Usability Questionnaire (TUQ) — At the end of the 2-week intervention (after session 4)
    Usability of the home-based robot-assisted gait rehabilitation service, measured with a questionnaire based on the Telehealth Usability Questionnaire (TUQ). Items are rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree); higher scores indicate better usability. Total and item scores are summarized.

Trial sites (1)

FacilityCityRegionStatus
Yongin Severance Hospital Yongin-si Gyeonggi-do Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07716475 on ClinicalTrials.gov ↗ ← All trials in South Korea